Takeaways: If governments adopt the CDA-AMC recommendation, Ubrelvy could gain public coverage and expand AbbVie’s migraine footprint in Canada, creating a stronger commercial path for...
Takeaways: The decision is especially meaningful for CELYSTRA because Québec is a high-prevalence region for FCS among French Canadians, so public coverage can quickly translate into concentrate...
Takeaways: Quaebec’s reimbursement of Vanflyta is a pivotal step toward pan‑Canadian access for a high‑value, biomarker‑targeted AML therapy. Market-wise, public funding acr...
Takeaways: Ontario’s reimbursement of Braftovi is a meaningful win for Pfizer and a strong signal for precision oncology adoption in Canada. It should accelerate uptake in a biomarker-defined me...
Takeaways: Gazyva’s reimbursement recommendation is a clear commercial win for Roche because it opens the door to public coverage in a high-need, specialty autoimmune market...
Takeaways Hemgenix has moved from theory to practice in Canada, with the first patient now treated outside a trial and public funding in place in Ontario and British Columbia. Market‑wise, this...
